methylprednisolone has been researched along with lfm a13 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carpenter, R; Cetkovic-Cvrlje, M; Chen, CL; Chen, H; Lisowski, E; Uckun, FM; Vassilev, A; Waurzyniak, B; Zheng, Y | 1 |
1 other study(ies) available for methylprednisolone and lfm a13
Article | Year |
---|---|
In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Topics: Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Antineoplastic Agents; Area Under Curve; Asparaginase; Biological Availability; Blotting, Western; Body Weight; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia, Experimental; Methylprednisolone; Mice; Mice, Inbred BALB C; Nitriles; Protein-Tyrosine Kinases; Rats; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vincristine | 2002 |